Is a
Clinical Study attributes
NCT Number
Health Conditions in Trial
Trial Recruitment Size
540
Trial Sponsor
Clinical Trial Start Date
September 30, 2024
0Primary Completion Date
December 15, 2027
0Study Completion Date
July 5, 2028
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Intervention Type
Drug0
Interventional Trial Phase
Phase 10
Official Name
A Randomized, Double-blind, Placebo-controlled Study, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally Administered Single Ascending Doses of ALN-HTT02 in Adult Patients With Huntington's Disease0
Last Updated
September 5, 2024
0Allocation Type
Randomized0
Intervention Model
Parallel Assignment0
Masking Type
Triple0
Masked Party
Investigator0
Care Provider0
Participant0
Other attributes
Intervention Treatment
ALN-HTT020
Placebo0
Study summary
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of a single dose of ALN-HTT02.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
